Category: News
-
Serum Profiling Making Mark on Predictive Medicine | Biodesix
Blood is a readily available and rich source of biomarkers that have the potential for use in diagnostics and companion diagnostics development, disease characterization and monitoring, and predictive drug response and toxicity analysis. Serum profiling using a variety of techniques to identify disease- or treatment-related proteins, antibodies, or oligonucleotides is leading to the identification of…
-
Getting Personal (Clinical Lab Products)
Personalized medicine, one goal of molecular diagnostics that is already being clinically realized, offers the opportunity to treat individuals on a case-by-case basis with greater efficacy and efficiency than ever before.
-
Biodesix Targeting Pharma for VeriStrat (GenomeWeb)
As Biodesix continues clinical validation and commercialization of its test to predict patient response to therapies for non-small cell lung cancer, it is looking to forge pharmaceutical partnerships to increase adoption of the test. The company is in the midst of conducting a trial in Italy to determine whether the test can determine which NSCLC…
-
Blood Test Helps Target Roche/OSI Lung Cancer Drug (Reuters)
Blood analysis good at predicting how tumours will respond; Proteomic test useful when doctors have no tumour tissue
-
CBSA BioBreakfast Focuses on Two CO Success Stories of 2009 (Rocky Radar)
CBSA’s May BioBreakfast allowed two of Colorado’s 2009 Bioscience success stories to share their stories. First up was Paul Beresford of Biodesix, a company playing in the diagnostic space. Dr. Beresford spoke to the attendees about Biodesix’s successful introduction of VeriStrat, a proteomic serum test used in lung cancer.
-
Highlights from the European Lung Cancer Conference | Biodesix
Watch the ELCC video highlights covering topics on tobacco control, translational research in lung cancer, novelties in the management of advanced NSCLC and radiotheraphy techniques. The highlights, which run for approximately 14 minutes, also present current issues with lung cancer tissue testing. This is followed by a discussion of VeriStrat, Biodesix proteomic serum test for…
-
Personalized Medicine Coalition Applauds Data Presentations at IASLC/ESMO ELCC
The Personalized Medicine Coalition (PMC) applauds the substantial number of new studies focusing on targeted approaches to the treatment of lung cancer presented at the second joint European Lung Cancer Conference of the International Association for the Study of Lung Cancer (IASLC) and the European Society for Medical Oncology (ESMO) in Geneva.
-
Blood Test May Help Fight Lung Cancer | Biodesix
A new blood test could improve the use of a popular lung cancer drug called erlotinib by allowing doctors to select which patients will react positively to the drug.
-
Biodesix: a New Way to Inform Cancer Treatment Selection (Rocky Radar)
“One data point doesn’t tell you very much in most cases,” comments David Brunel, CEO of Biodesix, a medical diagnostics company based in Broomfield, Colorado. This principle guides Biodesix’s approach to developing diagnostics which aim to identify a patient’s expected response to a particular therapeutic.
-
Your Blog Post Title Here…